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A polypeptide which induces hypermetabolism in normal synovial fibroblasts in 
tissue culture is described. The metabolic changes induced included a marked 
increase in hyaluronate formation, lactate formation and glucose uptake; forma- 
tion of soluble and fibrous collagen was depressed. An assay method is presented 
which permits quantitative comparisons of samples for connective tissue acti- 
vating peptide (CTAP) activity. The CTAP appeared to be widely distributed in 
human tissues, the amount of activity being a function of cell density. A role for 
CTAP in rheumatoid inflammation is proposed. 
Human synovial connective tissue cells 
can be activated in vitro by live leukocytes, 
extracts of human lymphocytes, polymor- 
phonuclear leukocytes, thrombocy tes, and 
extracts of embryonic human kidney cells 
and fibroblasts grown in tissue culture (1, 
2). The  term “activation” was used to 
focus attention on ‘the increased fibroblast 
metabolic activity induced by such materi- 
als, including marked stimulation oE hy- 
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aluronic acid formation, glucose uptake 
and lactate formation. It is clear that both 
allogeneic and syngeneic activator materi- 
als are effective in stimulating human syno- 
vial cells, and that a single exposure to 
such materials has effects that linger for 
weeks (2). Since this type of metabolic 
hyperactivity is known to be characteristic 
of rheumatoid synovitis (3,4), it is sug- 
gested that activator materials may play a 
central role in initiating and regulating the 
progression of the infEammatory process 
from the exudative to the reparative (pro- 
liferative) phase (2) .  
The present report provides information 
concerning the chemical nature of con- 
nective tissue activators and demonstrates 
the existence of these materials in several 
human tissue types. A striking difference in 
the responsiveness of synovial and dermal 
fibroblasts to activator substances suggests 
that there is a degree of heterogeneity in  
the elements of the connective tissue a&- 
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vating process, dependent on the anatomic 
location of the reactive connective tissue 
cells. A combined tissue culture- 
biochemical assay procedure is proposed 
which permits quantitative measurement 
and comparison of activator activity in 
biologic samples. Finally, the potential role 
of connective tissue activating peptide in 
regulating the transition from acute to 
chronic inflammation in the synovial mem- 
brane is discussed. 
MATERIALS AND METHODS 
Techniques for generating primary synovial and 
skin cell fibroblast cultures have been described 
earlier (5-7). Newer modifications of the author's 
procedures, including the methodology for frozen 
storage of fibroblasts using DMSO have been re- 
ported recently (8) , Where the author has deviated 
from the usual culture procedures, as in the assay 
technique for measurement of connective tissue 
activating peptide, these alterations of methodology 
are treated in the body of the text. The  sources of 
synovial tissue included amputations, arthrotomies, 
and punch biopsies, and the samples of other 
human tissues were obtained at  postmortem exami- 
nation. 
Protein was measured by the method of Oyama 
and Eagle(9) and DNA was measured through its 
deoxyribose content by the method of Burton (10) 
after the isolation of the desoxyribonucleoprotein 
(11). Glucose was measured by a glucose oxidase 
method (12) *, and lactic acid was measured by the 
method of Barker and Summerson (13). Hyaluron- 
ic acid was measured by isolating the polymer(14) 
and determining its uronic acid moiety by a 
colorimetric procedure (15) . Acid phosphatase wag 
measured in cellular extracts and culture media by 
measuring hydrolysis of a pnitrophenylphosphate 
substrate, and pglucuronidase was measured by 
virtue of its capacity to hydrolyze phenolphthalein 
pglucuronide (16,17). Cells examined for acid 
phosphatase and pglucuronidase activity were sus- 
pended at a concentration of 3.0 X 108 cells/l.O ml 
of pH 7.0, 0.05'M phosphate buffer, including 0.15M 
NaCI. This suspension was frozen and thawed three 
times and then centrifuged at 17,300 X g for 10 min 
'Glucostat, Worthington Biochemical Corpora- 
tion, Freehold, New Jersey. 
at 4°C. The supernatant fluid was used for enzy- 
matic assays. 
In  the section dealing with the development of 
methodology for assaying connective tissue activat- 
ing peptide through its ability to stimulate forma- 
tion of hyaluronic acid, a simplified procedure was 
used to isolate and measure hyaluronate. In  order 
to obviate the need for proteolysis before isolating 
the hyaluronate polymer, the assays were carried 
out in serum-free Eagles' synthetic medium. In the 
serum-free assay experiments, 1.7 ml of media was 
pipetted into a 30 ml Corex centrifuge tube. 
Cetylpyridinium chloride (5% CPC in 0.2M 
Na2S04) was added, 0.2 ml/sample, followed by 15 
ml of distilled water to reduce the ion coticeiitl'd- 
tion in the mixture to below the critical salt 
concentration of CPC-HA. The preparations were 
incubated for 1 hr at 37°C to promote optimal 
flocculation of the CPC-HA complex. The CPC-HA 
complex was sedimented by centrifugation at 17,300 
X g for 10 min at room temperature. The supern+ 
tant fluids were decanted, the precipitates in the 
Corex tubes were washed with approximately 25 ml 
of distilled water and again centrifuged at 17,300 X 
g for 5 min at room temperature. The wash was 
decanted and 20 ml of methanol containing 10% 
sodium acetate was added to each tube to facilitate 
conversion of the CPC-MA complex to sodium 
hyaluronate. This conversion requires approximate- 
ly 1 hr or less at 37°C. The sodium hyaluronate is 
sedimented by centrifugation at room temperature 
at 17,300 X g for 10 min and the supernatant fluid 
is decanted. One and two-tenths milliliters of a 
phosphate buffer, 0.05M. pH 7.0, containing 0.15M 
NaCl and testicular hyaluronidaset, 0.33 mg/ml, 
were added to each tube. T o  assure complete 
solution of the sodium hyaluronate, the mixture 
was allowed to stand for 1 hr at 37°C with mixing 
on a vortex at 15-min intervals. Uronic acid is 
measured in 1.0 ml of this solution using the 
method of Bitter and Muir (15). 
Connective tissue activating peptide was extracted 
from solid tissues by homogenizing the tissue in a 
Waring blender or a Virtis homogenizer using 1.0 g 
of solid tissue/lO ml of extraction buffer. The ex- 
traction buffer consisted of 0.05M phosphate buffer, 
pH 7.0 containing 0.15M NaCl supplemented by 
0.1% 8-mercaptoethanol and 0.001M EDTA (eth- 
ylenedinitrilo) tetraacetic acid, disodium salt. 
tworthington Biochemical Corporation, Freehold, 
New Jersey. 
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RESULTS crude DW water extract lost no activity 
Chemical Nature of Connective Tissue 
Activating Substanceb) 
Rheumatoid cell strain, DW, 10' 
cells/ml, was extracted for 2 hr in distilled 
water after three freeze-thaw cycles. The 
23,500 x g supernatant fluid (crude ex- 
tract) from this extraction proved to be a 
potent stimulator of connective 'tissue me- 
tabolism (Table 1). Disruption by sonic 
disintegration+ was equally effective in 
breaking the cells. Isotonic saline buffered 
(0.05M phosphate) at pH 7.0, as well as 
0.25M sucrose, were also satisfactory extrac- 
tion vehicles. As given in Table 1, the 
after 6 hr incubation at 37°C in 0.05M Tris 
buffer, pH 7.8, but virtually all biological 
activity was destroyed where the proteolytic 
enzyme pronaset (200 &ml) was included 
in the incubation mixture. In the controls 
where appropriate mixtures of buffers and 
pronase were added, no alteration of cul- 
ture performance was detected. Making an 
active extract 10% with respect to trichlo- 
roacetic acid destroyed all biological activi- 
ty, as did heating at 80°C for 30 min. 
Dialysis of a crude activator preparation 
against water for 16 hr at 6°C did not 
detract from the activity of the material, 
and the concentrated dialysis bath revealed 
- 
*Branson Sonifer, model S-75, Branson Instru- tpronase, a proteolytic enzyme derived from 
Streptornyces griseus was obtained from California 
Corporation for Biochemical Research, Los Angeles, 
ments Inc, Great Neck, Long Island. Sonication was 
carried out for 30 sec at Power 6 with the sample 
in an ice bath. California. 
Table 1. Destruction of Activator by a Proteolytic Enzyme* 
Glucose 
Final HA synthesis uptake 
fibroblast HA/flaskt rate (P  M /loe 
Culture additives count X 1W6 (pg) (ppglcelllday) cells/day) 
Saljne buffer + 4.01 114 28.3 1.95 
Tris buffer (3.78-4.27) (112-116) ( 27.2- 29.7) (1.84-2.06) 
Saline buffer + Tris 4.25 110 25.9 2.75 
buffer + Pronase (4.11-4.39) (108-112) ( 25.5- 26.3) (2.58-2.92) 
Tris buffer$ + 4.25 467 121.8 7.55 
Activator (3.73-4.00) (448-480) ( l l l .S l28 .9 )  (7.33-7.76) 
Activator incubated 3.99 488 122.6 7.79 
with Tris buffer 37" C (3.79-4.12) (466-511) (114.9-128.8) (7.48-8.10) 
for 6 hr. 







( 6.19- 6.51) 
5.07 






( 3.66- 5.55) 
* The values recorded are the means from 3 flasks, and the figures in parentheses represent the 
t HA is an abbreviation for hyaluronic acid. 
$The activator used in this experiment was derived fromrheurnatoid synovial cell strain DW. 
ranges of the observations. 
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no evidence, of dialyzable activity (Table 
2). When subjected to centrifugation' a t  
265,000 x g for 1 hr, the biological activity 
was found in the supernatant fluid while 
the pellet was essentially inactive (Table 
2). Ammonium sulfate precipitated biolog- 
ical active material over a range from 35 to 
90% saturation at pH 7.0, and was not 
helpful in recovering a purified active pro- 
tein in good yield. Chromatography of ac- 
tivator preparations on Sephadex G-25t 
and Bio-Gel P-61 columns equilibrated 
with 0.15M NaC1, 0.05M PO4, pH 7.0 
buffer demonstrated that the activator pro- 
tein was eluted with the excluded volume, 
suggesting that the molecular weight ex- 
ceeded 4000, in agreement with the dialysis 
*Beckman L2-65 Ultracentrifuge. 
TPharmacia Fine Chemicals, Inc, 800 Centennial 
$California Biochemical Corporation, Los Angeles, 
Ave. Piscataway, New Market, New Jersey. 
California. 
experiments. Similar chromatographic 
studies with Sephadex G 5 0  and Bio-Gel 
P-10 columns revealed retardation of the 
active principal, indicating a molecular 
weight of less than 10,000 and providing a 
useful tool for fractionating the p l y p e p  
tide activator from crude mixtures. 
The  semipurified activator peptide 
preparations tended to lose activity with 
repeated manipulation, even in frozen stor- 
age. Evidence was sought that a labile SH 
group was required for the biologic activity 
of the polypeptide connective tissue activa- 
tor, and the results are given in Table 3. In 
an alkylation experiment, a semipurified 
activator (41 p g  protein) was reacted with 
10.0 pg of iodoacetamide at p H  7.4 (PO4 
buffer) for 1 hr  a t  room temperature in a 
1.2 ml volume. The  alkylated activator, 
and an aliquot of untreated activator, were 
dialyzed overnight against water in  the 
dark to remove unbound iodoacetamide 








































None 3.35 175 17.4 
Activatort extract 3.23 521 53.8 
265,000 X g Supernatant 3.27 495 50.6 
265,000 x g Pellet 3.66 201 18.3 
(3.24-3.44) (164-180) (15.9-18.5) 
(3.05-3.40) (490-552) (50.4-56.8) 
fluid (3.13-3.52) (490-500) (47.4-52.9) 
(3.31-3.91) (194-206) (17.2-19.5) 
* The activator used in the dialysis experiment was derived from normal synovial strain WaK. 
t The activator used in this ultracentrifuge experiment was extracted from rheumatoid synovial cell 
strain DW. 
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Table 3. Evidence for Important 
Sulfhydryl Functions in the Connective 
Tissue Activating Polypeptide 
HA synthesis rate 
(fig HA/mg cell 
Culture additive prote in/24 hr) 
Buffer 6.5 
Activator peptide* 26.8 
Alkylated activator DeDtide 8.0 
Buffer 
Activatort + PCMBS 





* A chromatographic fraction of the HE,., cell 
strain taken from retarded volume of a P-10 
column. 
t A semi-purified fraction from HE,+ 
1 PCMB = pchloromercuribenzoate. (See text 
for explanation of manipulative procedures 
related to activator preparations.) 
and iodide. When 0.1 ml of each of these 
preparations (3.4 pg protein) was added to 
a normal synovial monolayer, the un- 
modified activator stimulated a threefold 
increase in the HA synthesis rate, while the 
alkylated protein was without effect. A sim- 
ilar experiment demonstrated that an effec- 
tive activator could be incubated at room 
temperature for 6 hr with 0.01M dith- 
iothreitol at p H  7.0 with no loss of activity, 
suggesting that exposed disulfide bonds are 
not critical to the biologic function of ac- 
tivator protein. T o  support the evidence 
from the iodoacetamide experiments sug- 
gesting that a sulfhydryl function was vital, 
the author attempted to block the biologic 
activity by forming a mercaptide with 
p-chloromercuribenzoate. A semipurified 
activator preparation (60 pg of protein) 
was reacted with 50 pg of p- 
chloromercuribenzoate at 25°C in 0.05M 
Tris buffer, p H  7.0. After 2 hr, the sample 
was split and one-half was exposed to 0.1M 
dithiothreitol, while the control received 
the vehicle during a second 2-hr incu- 
bation. Both preparations were dialyzed 
overnight against water at 6°C and then 
assayed for activity. As given in Table 3, 
the activator blocked by PCMB did not 
have the capacity to stimulate HA synthe- 
sis, whereas the preparation subsequently 
treated with dithiothreitol, in an attempt 
to remove the mercurial compound, did 
actually show a modest restoration of activ- 
ity. On the basis of these experiments sug- 
gesting that a reactive sulfhydryl group in 
the activator molecule was vital to the ex- 
pression of its biologic activity, the extrac- 
tion procedures were modified by including 
0.1% p-mercaptoethanol in the extracting 
vehicle. This lead to a marked increase in 
the amount of activator activity which 
could be recovered from ,tissue homog- 
enates, as much as a 100-fold increase in 
some instances, and provided indirect 
confirmation of the importance of the 
sulfhydryl function in the activator poly- 
peptide. 
The Behavior of Activated Synovial 
Connective Tissue Cells 
Since the earlier reports demonstrating 
the stimulation of hyaluronic acid and glu- 
cose metabolism induced by activator in 
cultivated synovial cells, the effects of con- 
nective tissue activation on collagen meta- 
bolism have been examined. A representa- 
tive experiment, given in Table 4, indicates 
that cultures exposed to an effective activa- 
tor form much less soluble and fibrous 
collagen in the face of increased hy- 
aluronate formation and glucose metabo- 
lism. As pointed out earlier (19), towards 
the end of a 9-day culture-period, the pro- 
portion of glucose uptake which can be 
accounted for as lactate tends to fall, sug- 
gesting a shift in the energy-producing pat- 
tern of the cell at the time when collagen 
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Table 4. Depression of Net Collagen 
Formation During Activation* 
Cultures 
Parameter measured 
Final fibroblast count, X 10-6 
HA/flask, sum of last two 
medium changes (pg) 
Soluble collagen/flask, sum of 
last two medium changes 
(.g) 
Fibrous collagen/flask bg )  
HA synthesis ratet bbg/cell/ 
Fibrous collagen synthesis 
Glucose uptake bM/1O6 cells/ 
Lactate output (pM/106 cells/ 
day) 
rate hg /ce l l /9  days) 
day)t 












*This experiment was carried out in 9-day 
cultures whose media was supplemented at 
each of 4 changes with 200pg ascorbate/ml of 
medium. The rationale for using this system for 
collagen study, and detailed presentation of the 
method of calculation are in recent reports (8,18). 
Activated cultures received the polypeptide during 
the final two medium changes. 
t Computed for the fourth (final) medium 
change. 
formation becomes a dominant activity. It 
is usually also true that the 7-9 day-interval 
reveals leveling off or deceleration of the 
hyaluronic acid synthesis rate. In  a sense, i t  
appears that the activator forces the con- 
nective tissue cell to continue its metabolic 
emphasis on hyaluronate formation sus- 
tained by a high rate of glycolysis, and in 
the process delays the shift to conditions 
favorable to collagen formation-an activi- 
ty known to dominate the latter portion of 
simple inflammation as well as being a 
terminal activity of the model culture sys- 
tem. 
I n  view of the interest in lysosomal en- 
zymes as possible mediators of tissue injury 
in aggressive inflammatory reactions, evi- 
dence was sought concerning the effect of 
connective tissue activation on two typical 
lysosomal enzymes, acid phosphatase and 
p-glucuronidase. As given in Table 5, 6 
separate experiments with two nonrheuma- 
toid cell strains provided an opportunity to 
make 10 comparisons. In  general, activated 
cells had more of a given lysosomal enzyme 
than did their controls. In  2 of 10 compari- 
sons, the controls were higher, in 5 of 10 
the increase in enzyme extracted from ac- 
tivated cells was minor, and in only 3 of 10 
comparisons was the amount of enzyme 
from activated cells more than double the 
control values. In  view of the variability of 
the enzyme measurements within a single 
cell strain, it is unwise to attach great 
significance to the relatively minor appar- 
ent increases in lysosomal enzymes induced 
by exposure to a single dose of activator. 
Assay of the culture media provided no 
evidence indicating significant release of 
Table 5. The Effect of Activation on 
Lysosomal Enzymes* 
Acid p hosphatase, 8-gl ucuron idase, 
units/l06 cells units/lO* cells 
Cell - 
source Control Activated Control Activated 
RN-Et 0.23 1.50 0.60 2.27 
RN-F 0.76 0.90 3.88 3.62 
RN-G 0.84 1.21 - - 
Ca W-D 1.39 1.21 - - 
Caw-F .66 .88 1.57 3.41 
Caw-G 0.65 1.09 2.21 2.38 
* In  each of six separate experiments the cells 
were exposed to an activator for 2 days before 
harvestingcells and media forcounting and chem- 
ical analysis. In each experiment, activation of 
the cells was confirmed by evidence of marked 
stimulation of HA formation in the activated 
flasks. 
t Denotes the passage status of a cell strain; 
E represents the fifth passage since separation 
from the donor explants. 
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these two enzymes into the extracellular 
milieu of either control or activated flasks. 
Specificity of the Synovial Fibroblast 
Response to Activator Materials 
In a preliminary experiment, skin fibro- 
blasts (J J-S) were exposed to an activator, 
prepared from cultivated rheumatoid syno- 
vial cells, in a plan to examine the effect of 
the peptide on sulfated mucopolysac- 
charide formation. Surprisingly, the hy- 
aluronate formation by these skin cells was 
virtually unaffected. Further, the sulfated 
mucopolysaccharide fraction isolated from 
the cellular mat (by proteolytic digestion 
and cetylpyridinium chloride fractionation 
(20)), was actually decreased 507' below 
that of the control flasks. This refractor- 
iness of skin fibroblasts to activator of syno- 
vial origin proved to be a reproducible 
phenomenon. As shown in Table 6, der- 
mal and synovial fibroblast strains were 
established from the same individual. On 
exposure to a modest amount of activa- 
tor, derived from rheumatoid synovial 
cells, the target synovial cells responded 
with a modest increase in hyaluronate and 
glucose metabolism. Skin fibroblasts from 
the same patient were not stimulated by 
the synovial activator. To further examine 
the capacity of skin fibroblasts to respond 
to activator materials, activator substance 
from human spleen, HE, tissue culture 
cells, and from two strains of dermal fibro- 
blasts were prepared. From Table 7, it is 
apparent that skin fibroblasts JJ-skin and 
Caw-skin showed increased formation of 
HA only in response to activator from 
dermal fibroblasts, although all of the ac- 
tivators were effective against synovial 
strain HH. It was interesting that the der- 
mal fibroblasts did show increased glucose 
uptake and lactate formation with virtually 
all types of activator while responding only 
to dermal activator with respect to in- 
creased HA formation. The JJ-skin strain 
responded equally to syngeneic and allo- 
geneic skin cell activator, but the Caw-skin 
strain was less responsive to allogeneic ac- 
tivator. I t  is noteworthy that in these ex- 
periments the magnitude of stimulation of 
HA synthesis by skin cell strains, when it 
did occur, was modest by comparison to 
synovial strains exposed to the same 
amount of the same activator preparations. 
Assay of Connective Tissue 
Activating Peptide (CTAP) 
To assay connective tissue activating 
peptide the following procedure was 
Table 6. Failure of Skin Cells to Respond to Synovial Activator 
Target HA synthesis Glucose uptake Lactate output 
strain source b 4 c e l  I/day) 
fibroblast Activator rate (P  M /loE bM/1@ 
cells/day) cells/day) 
Caw-Synovium Buffer 8.9 1.6 1.3 
Ca W-Sy novi u m DW Cells* 19.5 2.0 3.1 
Ca W-Skin Buffer 31.0 6.6 9.8 
Caw-Skin DW Cells 24.9 5.5 8.3 
( 7.9-10.1) (1.4 -1.7 ) (1.3- 1.3) 
(16.5-23.0) (1.98-2.01) (3.1- 3.1) 
(27.6-32.7) (6.5 -6.8 ) (8.6-10.9) 
(22.1-29.0) (5.3 -5 .8  ) (7.9- 8.7) 
* DW activator material from cultivated rheumatoid synovial cells was added in 50 pg amounts (equlva- 
lent to 5 X 1W cells) to the 10 rnl of media in each of the three experimental flasks. 
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Table 7. Selective Response of Skin Fibroblasts to Activator from Dermal Fibroblasts 
Target HA synthesis Glucoset uptake Lactatet output 
strain source (ppg/cell/day) protein/day) protein/day) 
fibroblast Activator rate (aM/mg (fiM/mg 
H H *-Synovium Buffer 17.8 3.2 7.7 
HH-Synovium Spleen 46.3 7.8 14.5 
HH-Synovium Ca W-Skin 70.2 8.4 16.4 







12.8 1.9 5.6 
14.0 4.8 10.9 
27.6 4.8 11.0 
Caw-Skin Buffer 25.2 8.6 13.8 
Caw-Skin JJ-Skin 27.6 6.2 17.2 
Caw-Skin Caw-Skin 32.5 8.7 21.8 





Buffer 10.1 5.0 7.1 
HE,-2 11.1 7.6 14.0 
JJ-Skin 27.6 4.8 11.9 
Caw-Skin 30.8 6.9 14.4 
~~ ~ ~ 
*The letters designating the fibroblast strains refer to the initials of the donors. 
t Measurements are in terms of pM/mg of cell protein/24 hr. 
adopted: normal target synovial cells were 
trypsin dispersed and planted out before 
noon to provide 4-6 hr  for attachment and 
spreading. Inocula consisted of 1.0 x 106 
cells/T-l5 flask, nourished by 2.0 ml of 
standard serum-containing media. After at- 
tachmen,t of the synovial fibroblasts to the 
flask surface, the standard media was re- 
placed by Eagles’ synthetic medium 
buffered to p H  7.4 with 0.02M HEPES* 
buffer and supplemented as usual with 
penicillin, streptomycin and Lglutamine. 
Omission of serum simplifies the subse- 
quent analysis of the medium for hy- 
aluronate and prevents cell multiplication. 
Experimental flasks received 0.1 to 0.3 ml 
of the test sample, and duplicate control 
flasks received the same volume of the 
*N-2-Hydroxyethylpiperazine-N-2-EthanasiiIfonic 
acid, from Calbiochem, Los Angeles, California. 
appropriate vehicle. Incubation was car- 
ried out at 35-37°C. The  progressive incre- 
ment in hyaluronate formed by activated 
cultures is illustrated in Fig 1. T h e  amount 
of hyaluronate formed by a culture in- 
creased steadily with incubation time for at 
least 48 hr, at which point glucose in the 
medium was not yet exhausted. To  define 
the relationship between concentration of 
activator peptide and culture response in  
terms of hyaluronate synthesis, a series of 
increasing concentrations of activator pep 
tide were tested, terminating the assay at 
40-hr incubation. As shown in Fig 2, the 
early portion of the dose-response curve is 
essentially zero order and then becomes 
curvilinear with no further increase in hy- 
aluronate formation at  the higher concen- 
trations of activator. A unit of activator 
activity is defined as that amount which 
induces a culture to form 10 pg of hy- 
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aluronate/mg of cell protein/24 hr more 
than the nonactivated control cultures. 
Such measurements must be made with 
dilute preparations of activator whose ac- 
tivity will fall on the linear portion of the 
dose response curve. One of the major 
difficulties with this system lies in intrinsic 
differences among different target cell 
strains (indicator strains). Dose-response 
curves generated by different cell strans in 
response to a single activator are usually 
similar, but seldom identical. Measure- 
ments made on a group of unknown sam- 
ples will fall into the same rank order 
when measured against different indicator 
cell strains, but the actual units of activity 
of a given preparation measured against 
two different indicator cell strains may vary 
by as much as 50%. I t  is therefore impor- 
tant to attempt to use one cell strain 
routinely as an indicator strain, or if more 
than one strain is to be used, to assure 
oneself of the equivalent performance of 
the multiple cell strains. In any case, when 
a quantitative comparison between two or 
200 r 
I I 1 I I I I 
0 8 16 24 32 40 48 
Time- in Hours 
Fig 1. Control flasks showed only a minor increment 
in HA as a function of time, while activated flasks 
demonstrated more than a sixfold increase over the con- 
trols by 4 8  hr. Each point is the mean of duplicate flasks. 
I I I I I 
0 5 10 15 20 25 
) l L  of %Activator" 1 Flask 
Fig 2. A normal synovial strain responded to increasing 
amounts of activator from a rheumatoid synovial strain, 
DW, by producing increasing amounts of HA until a maxi- 
mal rate was achieved. 
more samples is required, accuracy would 
be improved by assaying them simultane- 
ously against the same indicator cell strain. 
The following relation may be used to 
calculate the concentration of activator in 
test samples: 
A, - A, 
10 x v units of activator/ml = 
in which A, = hyaluronic acid synthesis 
rate in the stimulated culture corrected to 
pg hyaluronate/mg cell protein/24 hr; A, is 
this measurement in the unstimulated con- 
trol flasks; and V = the volume of activator 
material added to the standard test system 
in milliliters. 
Distribution of Activator Peptide 
in Human Tissues 
Quantitative data concerning the con- 
centration of activator peptide in several 
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Table 8. Connective Tissue Activating Peptide (CTAP) in Human Tissues 
CTAP, Units/100 pg DNA 
Fibroblast 
assay Lymph 
Patient Diagnosis strain Spleen Liver node Kidney Heart Lung 
OD Carcinoma of breast, Caw-H 6.4 5.7 - 6.5 7.4 - 
ascites and acute pas- 
sive congestion of lungs 
- - - FL Cirrhosis, brain infarct HH-G 12.5 6.9 2.4 
Jur Pneumonia HH-G 7.2 
CB Gunshot wound HH-G 8.6 7.2 
EFr Chronic renal failure, HH-H 2.7 1.7 13.1 
- 1.6 - - - 
- - - - 
- - - 
Hernod ialysis 
acute passive congestion 
of spleen 
monary fibrosis, Predni- 
sone 
- - - 7.5 EP Congenital heart disease, HH-H 12.0 3.5 
- - - JC Diffuse interstitial pul- HH-F 5.3 2.3 1.9 
- - - - - MW* Felty's syndrome HH-G 8.6 
KB* Felty's syndrome HH-G 6.5 
MW Felty's syndrome FS-E 14.4 
KB Felty's syndrome FS-E 10.6 
- - - - - 
- - - - - 
- - - - - 
Mean 8.6 4.6 5.8 7.0 7.4 1.6 
* Made available through the courtesy of Dr. John L. Decker, Chief of the Arthritis and Rheumatism 
Branch, National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, 
Maryland. 
human tissues is given in Table 8. Since i t  
was clear that the activator peptide was a 
function of the number of cells extracted, 
the concentration of activator has been 
related to the amount of DNA found in the 
tissues. Examined in this way, there a p  
peared to be no startling differences among 
the tissues examined with respect to the 
concentration of activator peptide. The 
variation in determinations of CTAP result- 
ing from measurement with different indi- 
cator cell strains may be apprecioted from 
Table 8 where data from patients M W  and 
KB are recorded. It is noteworthy that the 
ratio of the measurements, MW KB was 
virtually constant, being 1.32 in the first 
measurement and 1.36 in the second in- 
stance. Since the determinations in Table 8 
may be influenced by pathologic processes 
and drug therapy, no conclusions about 
normal tissue levels of CTAP should be 
drawn from this random sample. It was 
interesting that the highest splenic values 
were found in circumstances associated 
with congestion or hyperplasia of the or- 
gan, while the lower values were associated 
with glucocorticoid therapy (JC) and a 
protracted debilitating illness (EFr). In  
patient Jur normal lung exhibited 1.6 units 
of CTAP/100 pg DNA, while- acutely 
inflamed lung had 2.5 units of CTAP/100 
As shown in Table 9, similar concentra- 
tions were found in both normal and rheu- 
matoid synovial tissue. The mean value for 
activator peptide extracted from rheuma- 
pg DNA. 
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Table 9. Connective Tissue Activating Peptide (CTAP) in Non-Rheumatoid and Rheumatoid Synovium 
DNA CTAP CTAP 
bg /g  (U n its/g (Un its/100 
Patient Diagnosis: Treatment tissue) tissue) fig DNA) 
Ca W Normal 0 188 33.1 17.6 
HH Normal 0 332 14.5 4.4 
FS Normal 0 381 14.7 3.9 
JaK TA 0 366 22.4 6.1 
J Ka TA 0 189 13.0 6.9 
WA DJD Oral steroids 189 0.0 0.0 
CF Ank. Spon. lndomethacin 592 11.0 1.9 
TH t ? JRA Physical therapy 343 19.0 5.5 
Mean 323 16.0 5.8 
WH RA IA steroids Hydroxy. 482 27.3 5.7 
c hloroq u in 
EF RA IA steroids 422 26.9 6.4 
JJ RA IA steroids 618 3.4 0.6 
EP RA IA Steroids, Indometha- 757 0.0 0.0 
IK RA Oral steroids 617 32.0 5.3 
HD RA Oral, IA steroids 569 24.5 4.3 
MaH RA Phenyl butazone, 1019 19.7 1.9 
cin Methotrexate 
H yd roxyc hloroqu in 
Mean 641 19.1 3.5 
* TA = Traumatic arthritis, DJD = degenerative joint disease, JRA = juvenile rheumatoid arthritis 
t TH is a 15-year-old boy with monarticular arthritis of uncertain etiology, trauma and JRA appearing 
and RA = rheumatoid arthritis, IA = intra-articular. 
most I i kely. 
toid synovium was somewhat less than that 
from controls, a finding that may be related 
to the modality of treatment. All of the 
very low measurements of CTAP in synovi- 
a1 membrane were associated with oral 
and/or intraarticular glucocorticoid thera- 
py, including a patient (WA) treated with 
oral steroids for degenerative joint disease. 
I n  addition to the quantitative measure- 
ments presented in tabular form, activator 
peptide was demonstrated in human skel- 
etal muscle and in established tissue 
cul'ture cell strains such as HEp2, Chang 
liver, and J-Il l  malignant monocytes. The 
BHK hamster kidney fibroblast, the LM 
mouse fibroblast and a transformed human 
synovial cell strain were essentially without 
activity . 
DISCUSSION 
Current data indicate that the connec- 
tive tissue activating substance is a water 
and saline soluble polypeptide with a 
molecular weight between 4000 and 10,000. 
It possesses one or more labile sulfhydryl 
groups per molecule which are essential to 
those biologic actions which we have 
studied. In  disrupted cell preparations, the 
connective tissue activating peptide 
(CTAP) is found in the nonparticulate 
fraction after centrifugation at 265,000 x g. 
Extraction of CTAP activity from human 
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tissues in the absence of a thiol (dithiothre- 
itol or p-mercaptoethanol) is difficult, and 
yields low levels of evanescent activity. The 
rapid disappearance of CTAP from the 
disordered environment of a tissue homog- 
enate probably depends to a significant 
degree on the lability of sulfhydryl func- 
tions which readily undergo.. oxidation, 
alkylation, participate in disulfide inter- 
change reactions, and form mercaptides. It 
seems unlikely that CTAP activity would 
persist for long in an extracellular site 
following injury and cell disruption, or that 
i t  could diffuse very far in an active form. 
It is not surprising then, that the CTAP 
was not detected in serum or cell-free joint 
fluid. 
The peculiar sensitivity of fibroblasts 
from synovial membrane to the action of 
CTAP from diverse sources is unexplained. 
It is intriguing to recall that synovitis is 
frequently associated with granulomatous 
or proliferative processes in other organ 
systems, including sarcoidosis, ulcerative 
colitis and psoriasis, clinical entities where- 
in the articular manifestations often sub- 
side with control of the primary disease. As 
shown in this report, dermal fibroblasts are 
less sensitive and apparently have specific 
requirements best found in extracts of der- 
mal cells themselves, adding yet another 
dimension to the array- of differences 
known to exist between fibroblasts of syno- 
vial and dermal origin (7,21). A survey of 
the activation process in fibroblasts from 
multiple organs and tissues is an important 
area for further study, and in this con- 
nection it is interesting that CTAP from 
rheumatoid synovial strain DW induced 
moderate hyperfunction in fibroblasts de- 
rived from human retroorbital tissue (22). 
The assay procedure for measurement of 
CTAP is relatively rapid, reproducible and 
permits quantitative comparisons of biolog- 
ic samples. The 40-hr incubation of the test 
sample with an indicator culture may be 
planned to terminate at 8-9 AM, which 
allows adequate time for measurment of 
cell protein and medium HA within 48 hr 
of initiation of the assay. All oE the manip 
ulations of hyaluronic acid in the serum- 
free procedure, except the final colorime- 
try, may be carried out in the Corex centri- 
fuge tube which initially received the medi- 
um sample. 
It is clear from the tissue survey that 
CTAP is widely distributed, and the abso- 
lute amount found in a given tissue is 
significantly related to cell density. When 
CTAP from a given set of cells is permitted 
to act on synovial fibroblasts, the latter cells 
are promptly induced to exhibit hyperme- 
tabolism characterized by a 340-fold in- 
crease in hyaluronic acid formation, 
marked stimulation of glucose uptake, lac- 
tate formation and hydrogen ion liber- 
ation. Concurrent with this burst of hyper- 
metabolism, formation of soluble and 
fibrous collagen is depressed. 
If one views simple inflammation as an 
integrated sequential process designed to 
repair an injury, it is reasonable to postu- 
late signal mechanisms to turn on the ana- 
bolic (proliferative or reparative) phase 
of inflammation and to expect the origin of 
this signal mechanism to lie in the an- 
tecedent (exudative) phase. Such a role for 
CTAP (activator) in synovial inflamma- 
tion is shown diagrammatically in Fig 3. 
The activator peptide is visualized as aris- 
ing from necrotic tissue cells and from 
leukocytes of the exudative stage, and in- 
ducing increased energy metabolism and 
mucopolysaccharide (HA) formation in 
the synovial connective tissue cells. Clearly, 
all of the events of the reparative phase 
are not stimulated by CTAP. I t  would not 
be unreasonable to speculate concerning 
the existence of a family of activators work- 
ing in sequence to complete the anabolic 
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AN INTEGRATED VIEW OF THE INFLAMMATORY PROCESS 
















Flg 3. An abbreviated schematic summary of the exudative and reparative phases of the inflammatory 
process, showing an activator substance regulating the transition from one to the other. 
process. Of particular interest in the con- 
text of rheumatoid inflammation is an an- 
alysis of the consequences of prolonged, 
excessive stimulation by CTAP. One would 
expect chronic overproduction of hy- 
ahronate and increased synovial energy 
metabolism, as seen in garden variety rheu- 
matoid synovitis. In  addition, the tendency 
of CTAP to freeze metabolic activities of 
synovial cells a t  the level of mucopolysac- 
charide formation, and to depress collagen 
formation, might well delay the completion 
of the reparative process. Chronic hyper- 
stimulation of rheumatoid synovial tissue 
may be a consequence of CTAP derived 
from polymorphonuclear cells of the syno- 
vial fluid, lymphoid cells of the stromal 
infiltrate, and possibly an augmented con- 
tent of CTAP in the surface synovial cells 
themselves (23). Future measurements of 
CTAP in synovial tissue would be most 
useful i f  the confusion incident to drug 
effects could be relieved, and i f  the superfi- 
cial and deep layers were examined sepa- 
rately. I t  is possible that turn over studies 
rather than single time point measure- 
ments will be required to adequately assess 
the role of activator in rheumatoid synovi- 
tis. 
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